Drug Combination Details
| General Information of the Combination (ID: C15117) | |||||
|---|---|---|---|---|---|
| Name | Lycopene NP Info | + | Anti-PD-1 antibody Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | IFNG | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | JAK-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | STAT3 | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | Lewis lung carcinoma (LLC) cells (1*106) were injected in the rear flak of C57BL/6 mice. | |||||
| Experimental
Result(s) |
Lycopene improves the efficiency of anti-PD-1 therapy via activating IFN signaling of lung cancer cells. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Lycopene improves the efficiency of anti-PD-1 therapy via activating IFN signaling of lung cancer cells. Cancer Cell Int. 2019 Mar 21;19:68. | |||
